Zai Lab Soars 10.83% on Clinical Trial Success

Zai Lab's stock surged 10.83% in pre-market trading on June 4, 2025, driven by positive developments in its clinical trials and regulatory approvals.

Zai Lab recently presented updated Phase 1 data for ZL-1310, demonstrating strong anti-tumor activity and a manageable safety profile. This includes intracranial responses, which are particularly encouraging for the treatment of brain metastases.

The company is also preparing to initiate a pivotal Phase 3 trial for ZL-1310 in second-line small cell lung cancer, targeting a 1.6 mg/kg dose. This trial is a significant step forward in the development of ZL-1310 as a potential treatment for this aggressive form of cancer.

Additionally, Zai Lab has received U.S. FDA Fast Track Designation for ZL-1310, a DLL3-targeted antibody-drug conjugate, for the treatment of extensive-stage small cell lung cancer. This designation is expected to expedite the development and review process for ZL-1310, potentially bringing this innovative therapy to patients more quickly.